OmniaMed

Who owns OmniaMed?

OmniaMed is currently owned by DPE Deutsche Private Equity through DPE Fund II (2013 vintage), since 2013.

Hand-verified · updated 2026-07-03

About OmniaMed

OmniaMed Communications is a healthcare-focused medical communications and continuing medical education group that connects pharmaceutical and healthcare clients with clinicians through trusted digital platforms and clinical communities. Its portfolio spans widely used properties including GPnotebook, an indexed clinical reference used across UK primary care, Diabetes on the Net, Wound International and Wound UK, the British Journal of Cardiology and a range of nursing titles, delivering targeted advertising, webcasts, podcasts, video and promotional content hubs for healthcare professionals. According to its own disclosures, the platform reaches more than 400,000 doctors and nurses each month across the UK, the United States and Australia. The group operates from offices in London, Lincolnshire in Illinois, Sydney and Johannesburg, positioning it as a market leader in Germany and the UK for CME and clinician-education services.

Ownership journey

OmniaMed traces its roots to a UK medical education and publishing business founded in 2004, later built into a cross-border digital knowledge and education platform for doctors, nurses and allied health professionals. In 2013 DPE Deutsche Private Equity acquired the company through its DPE Fund II, backing a management buyout in what was the firm's first education-sector deal and its first UK investment, alongside the incumbent management team. DPE Fund II remains an active shareholder and OmniaMed is still listed as a current portfolio company; no exit or secondary transaction has been recorded. The investment anchored a buy-and-build strategy under DPE ownership.

Under PE ownership

Under DPE ownership OmniaMed has pursued growth through acquisition and platform expansion, bolting on Schofield Healthcare Media, a UK provider of medical education and conference services, with one of the sellers reinvesting equity into the enlarged group. The strategy widened the company from its publishing and events origins into a portfolio of digital clinical communities and reference tools serving primary care, diabetes, wound care, cardiology and nursing audiences. Reported turnover reached 9.8 million euros in 2022, and the platform's monthly reach has grown to more than 400,000 healthcare professionals across three continents, per company and investor disclosures. The buy-and-build approach extended the group's geographic footprint into the United States and Australia alongside its established UK base.